China’s biotechnology M&A transactions have almost doubled this year, while public stock offerings surged as investors scour for opportunities amid a global rush to develop a cure for Covid-19 disease …
( read original story …)
The Shanghai News
China’s biotechnology M&A transactions have almost doubled this year, while public stock offerings surged as investors scour for opportunities amid a global rush to develop a cure for Covid-19 disease …
( read original story …)